Editas Medicine, Inc. — fact timeline

Editas Medicine, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditor at the 2026-06-17 meeting.

“The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 64,686,839 774,471 392,610 0”

Editas Medicine, Inc. shareholders approved Advisory vote on executive compensation at the 2026-06-17 meeting.

“The Company’s stockholders approved, on an advisory basis, the compensation paid to its named executive officers. The results of the stockholders’ non-binding, advisory vote with respect to compensation paid to the Company’s named executive officers were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 32,914,258 6,322,885 212,587 26,404,190”

Editas Medicine, Inc. shareholders approved Election of Class I directors at the 2026-06-17 meeting.

“The Company’s stockholders elected Bernadette Connaughton and Elliott Levy, M.D., to serve as Class I directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class I directors were as follows: Votes For Votes Withheld Broker Non-Votes Bernadette Connaughton 28,660,181 10,789,549 26,404,190 Elliott Levy, M.D. 37,095,058 2,354,672 26,404,190”

Editas Medicine, Inc. entered into Underwriting Agreement with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC valued at combined public offering price of $2.25 (effective 2026-05-26).

“On May 26, 2026, Editas Medicine, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC as representatives of the underwriters named therein (the “Underwriters”), relating to an underwritten public offering of 55,555,556 shares”

Editas Medicine, Inc. reported the first quarter 2026 results: net income net loss attributable to common stockholders was $25.0 million , or $0.26 per share.

“expenditure requirements into the third quarter of 2027. First Quarter 2026 • For the three months ended March 31, 2026 , net loss attributable to common stockholders was $25.0 million , or $0.26 per share, compared to net loss of $76.1 million , or $0.92 per share, for the same period in 2025 . • Collaboration and other research and development revenues”

Editas Medicine, Inc. engaged PricewaterhouseCoopers LLP as its auditor.

“appointed PricewaterhouseCoopers LLP (“PwC”) to serve as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2026”

Editas Medicine, Inc. dismissed Ernst & Young LLP as its auditor.

“dismissed Ernst & Young LLP (“Ernst & Young”) as the Company’s independent registered public accounting firm, effective immediately”

Editas Medicine, Inc. reported financial results for the fourth quarter and full year 2025.

“On March 9, 2026 , Editas Medicine, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter and year ended December 31, 2025 and other business highlights.”

Editas Medicine, Inc.: Increased authorized shares of capital stock from 200,000,000 to 395,000,000 and common stock from 195,000,000 to 390,000,000 (effective 2025-06-02).

“At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation (the “Certificate of Amendment”) to increase the number of authorized shares of the Company’s capital stock from 200,000,000 to 395,000,000 and the number of authorized shares of the Company’s common stock from 195,000,000 to 390,000,000. The additional common stock authorized by the Certificate of Amendment has rights identical to the Company’s currently outstanding common stock. The Company filed the Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on June 2, 2025.”

Amy Parison was appointed as Senior Vice President, Chief Financial Officer and Treasurer at Editas Medicine, Inc..

“In connection with Mr. Lucera’s resignation, on March 19, 2025 the Company appointed Amy Parison, Senior Vice President, Finance as Senior Vice President, Chief Financial Officer and Treasurer of the Company, to be effective as of the close of business on March 28, 2025.”

Erick Lucera departed as Executive Vice President, Chief Financial Officer at Editas Medicine, Inc..

“On March 18, 2025, Erick Lucera, Executive Vice President, Chief Financial Officer of Editas Medicine, Inc. (the “Company”) informed the Company that he will be resigning from his position effective March 28, 2025.”

Editas Medicine, Inc. announced a restructuring with charges of approximately $14.0 million to $18.0 million (approximately 180 positions, or approximately 65%).

“The Company additionally expects to incur costs of approximately $14.0 million to $18.0 million related to the Reduction, primarily consisting of severance payments and employee benefit costs.”

Editas Medicine, Inc. announced a restructuring with charges of approximately $55.0 million to $70.0 million affecting reni-cel program.

“The Company expects to incur costs of approximately $55.0 million to $70.0 million related to the Discontinuation, as it completes the wind-down of various activities related to clinical development of reni-cel, including contract termination costs, impairment charges and non-cash charges, and may also incur additional costs not currently contemplated due to events that may occur as a result of or that are associated with the Discontinuation.”

Editas Medicine, Inc.: Amended and restated by-laws to clarify definition of 'acting in concert' and make other clarifying changes in accordance with Rule 14a-19 under the Exchange Act (effective 2024-12-06).

“On December 6, 2024, the Board of Directors of Editas Medicine, Inc. (the “Company”) unanimously adopted Amended and Restated By-Laws of the Company (the “By-Laws”), effective immediately, to clarify the definition of “acting in concert” as used therein, and to make certain other clarifying changes in accordance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).”

Akshay Vaishnaw resigned as Director at Editas Medicine, Inc..

“On June 27, 2024, Akshay Vaishnaw informed the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”) of his resignation from the Board effective as of June 30, 2024.”

Editas Medicine, Inc. reported first quarter 2024 results: net income net loss of $62.0 million, EPS -$0.76.

“For the three months ended March 31, 2024, net loss attributable to common stockholders was $62.0 million, or $0.76 per share, compared to net loss of $49.0 million, or $0.71 per share, for the same period in 2023.”

Editas Medicine, Inc. reported the fiscal quarter ended September 30, 2023 results: revenue $5.3 million, net income $45.0 million net loss, EPS $0.55 per share.

“$0.55 per share, compared to net loss of $55.7 million, or $0.81 per share, for the same period in 2022. • Collaboration and other research and development revenues increased to $5.3 million for the three months ended September 30, 2023, compared to $42.0 thousand for the same period in 2022. The increase is primarily related to an upfront payment for the”

Bruce E. Eaton departed as Chief Technology Officer and Chief Business Officer at Editas Medicine, Inc..

“Bruce E. Eaton, Ph.D., Executive Vice President, Chief Technology Officer and Chief Business Officer of the Company, agreed that Dr. Eaton will step down as Chief Technology Officer and Chief Business Officer effective January 2, 2024”

Editas Medicine, Inc. reported second quarter 2023 results: net income $40.3 million, EPS $0.56 per share.

“For the three months ended June 30, 2023, net loss attributable to common stockholders was $40.3 million, or $0.56 per share, compared to net loss of $53.5 million, or $0.78 per share, for the same period in 2022.”

Editas Medicine, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C. valued at approximately $117.2 million (effective 2023-06-14).

“On June 14, 2023, Editas Medicine, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C. as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering of 12,500,000 shares (the “Underwritten Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).”

Michelle Robertson departed as Executive Vice President and Chief Financial Officer at Editas Medicine, Inc..

“who stepped down as the Company’s Chief Financial Officer effective May 16, 2023”

Erick J. Lucera was appointed as Executive Vice President and Chief Financial Officer at Editas Medicine, Inc..

“On May 16, 2023, Editas Medicine, Inc. (the “Company”) appointed Erick J. Lucera as Executive Vice President and Chief Financial Officer of the Company, effective May 17, 2023, succeeding Michelle Robertson as Executive Vice President and Chief Financial Officer of the Company”

Editas Medicine, Inc. reported the first quarter 2023 results: net income net loss attributable to common stockholders was $49.0 million, or $0.71 per share, EPS $0.71 per share.

“Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today reported business highlights and financial results for the first quarter 2023.”

Elliot Levy was appointed as Independent Director at Editas Medicine, Inc..

“appointed Elliot Levy, M.D. as an independent director, effective immediately.”

Editas Medicine, Inc.: Amended and restated bylaws to conform with recent DGCL amendments and universal proxy rules (effective 2023-03-10).

“On March 10, 2023, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an amendment and restatement of the Amended and Restated By-Laws of the Company (as so amended and restated, the "Amended and Restated By-Laws").”

James C. Mullen departed as Executive Chairman of the Board at Editas Medicine, Inc..

“On March 8, 2023, James C. Mullen, the Executive Chairman of the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”) notified the Board that he does not intend to seek re-election as a director of the Company when his current term ends at the 2023 Annual Meeting of Stockholders.”

Editas Medicine, Inc. reported the full year 2022 results: revenue $19.7 million, net income $220.4 million, EPS $3.21 per share.

“million, or $3.21 per share, compared to $192.5 million, or $2.85 per share, for the same period in 2021. ​ ● Collaboration and other research and development revenues were $19.7 million for 2022, compared to $25.5 million for 2021. The $5.8 million decrease was primarily attributable decreased revenue recognized in the year ended December 31, 2022 related to the”

Editas Medicine, Inc. reported the three months ended December 31, 2022 results: revenue $6.5 million, net income $60.7 million, EPS $0.88 per share.

“to net loss of $41.4 million, or $0.61 per share, for the same period in 2021. ​ ● Collaboration and other research and development revenues decreased by $6.0 million to $6.5 million for the three months ended December 31, 2022, compared to $12.5 million for the same period in 2021. The decrease was primarily attributable to a decrease in collaboration”

Mark S. Shearman departed as Chief Scientific Officer at Editas Medicine, Inc..

“On January 7, 2023, Editas Medicine, Inc. (the “Company”) and Mark S. Shearman, Ph.D., Executive Vice President and Chief Scientific Officer of the Company, agreed that Dr. Shearman will step down as Chief Scientific Officer effective March 31, 2023.”

Editas Medicine, Inc. reported the three months ended September 30, 2022 results: revenue $42 thousand, net income $55.7 million, EPS $0.81 per share.

“or $0.81 per share, compared to net loss of $39.1 million, or $0.57 per share, for the same period in 2021. ​ ● Collaboration and other research and development revenues were $42 thousand for the three months ended September 30, 2022, compared to $6.2 million for the same period in 2021. The 2021 period included revenue recognized for an opt-in by Bristol Myers”

James C. Mullen changed role as Executive Chair at Editas Medicine, Inc..

“Mr. Mullen will continue to serve as Executive Chair of the Company’s Board of Directors (the “Board”).”

Gilmore O'Neill was appointed as director at Editas Medicine, Inc..

“Also on April 12, 2022, the Board, upon recommendation of the Board’s Nominating and Corporate Governance Committee, increased the size of the Board by one member and appointed Dr. O’Neill as a director, effective as of the Effective Date.”

Gilmore O'Neill was appointed as President and Chief Executive Officer at Editas Medicine, Inc..

“On April 12, 2022, Editas Medicine, Inc. (the “Company”) appointed Gilmore O’Neill, M.B., M.M.Sc. as President and Chief Executive Officer of the Company, succeeding James C. Mullen as President and Chief Executive Officer of the Company, effective as of June 1, 2022 (the “Effective Date”).”

Lisa Michaels was terminated as Chief Medical Officer at Editas Medicine, Inc..

“On February 7, 2022, Lisa Michaels’ employment with Editas Medicine, Inc. (the “Company”) as Chief Medical Officer was terminated, effective immediately.”

Bernadette Connaughton was appointed as Independent Director at Editas Medicine, Inc..

“On October 26, 2021, the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, increased the size of the Board by one member and appointed Bernadette Connaughton as an independent director, effective immediately.”

Emma Reeve was appointed as independent director at Editas Medicine, Inc..

“On September 3, 2021, the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, increased the size of the Board by one member and appointed Emma Reeve as an independent director, effective immediately.”